Moreover, Xie and colleagues found that METTL3 knockdown decreased FASN mRNA levels, which in turn inhibited lipogenesis, leading them to believe that METTL3 would be a possible therapeutic target for treating NAFLD.14,59 However, there are no effective therapies that target METTL3 to treat NAFLD currently; therefore, additional research is required to create innovative medications that target it as well as other m6A modulators. Here, FASN is linked to metabolic dysfunction-associated steatotic liver disease.